Innovent Biologics Inc (6IB) — Strategic Asset Allocation Index
Innovent Biologics Inc (6IB) has a Strategic Asset Allocation Index of 38.8% as of June 2023. Strategic assets (PP&E of €4.19 Billion plus long-term investments of €-) total €4.19 Billion, measured against net assets of €10.78 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Innovent Biologics Inc Strategic Asset Allocation Index (2018–2022)
This chart shows how Innovent Biologics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of June 2023, the index stands at 38.8%, representing strategic assets of €4.19 Billion against net assets of €10.78 Billion EUR. Explore cash efficiency ratio of Innovent Biologics Inc to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Innovent Biologics Inc (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Innovent Biologics Inc from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 6IB market cap.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 35.7% | €3.83 Billion | €3.83 Billion | €- | €10.73 Billion | ▲ +5.7 pp |
| 2021 | 29.9% | €3.09 Billion | €3.09 Billion | €- | €10.33 Billion | ▲ +8.1 pp |
| 2020 | 21.8% | €1.91 Billion | €1.91 Billion | €- | €8.78 Billion | ▼ -8.4 pp |
| 2019 | 30.2% | €1.44 Billion | €1.44 Billion | €- | €4.76 Billion | ▲ +4.5 pp |
| 2018 | 25.7% | €1.08 Billion | €1.08 Billion | €- | €4.19 Billion | — |